Scientific Portal (Research Grant)


Sedana Medical Research Grant

One of the missions for Sedana Medical is to improve patient outcome through medical innovation. Sedana Medical Research Grant (SMRG), established in 2019, is an integral part of this mission. This is an opportunity for the scientific community to increase its understanding of sedation in critical ill patients in intensive care.

Up to three individual academic researchers will be awarded a grant of between €10 000 and €30 000 per year, for up to two years. The grant will put priority to research targeting effects of inhaled anaesthetics in mechanically ventilated patients.


Sedana Medical Research Foundation 2020 – Awarded projects

Many well-written and interesting applications were submitted. After independent scientific review by two external reviewers and the Clinical Development Committee at Sedana Medical, three research projects were prioritized for funding in 2020.

Title: Effects of sevoflurane on extravascular lung water and pulmonary vascular permeability in patients with acute respiratory distress syndrome.
Investigators: Dr Christopher Lai, MD, Professor Xavier Monnet, MD, Tài Pham, MD PhD, Medical Intensive Care Unit, Hôpital Bicêtre, University Paris-Saclay, Le Kremlin-Bicêtre, France.
Patients with ARDS and treated with sevoflurane have reduced lung inflammatory response and improved oxygenation. Preclinical studies of inhaled sedation in experimental ARDS have shown reduction in lung edema but this has not been studied in humans. In this study it is hypothesized that the mechanism behind sevoflurane-mediated improved oxygenation in ARDS is reduced lung edema. This research project will evaluate the effects of inhaled sedation via the AnaConDa, compared with propofol, on extravascular lung water index (EVLWi) and the pulmonary vascular permeability index (PVPI) in ARDS patients. The aim of the study is to increase the understanding of the lung-protective effects of inhaled sedation in ARDS.

Title: Volatile short-term sedation in patients undergoing cardiac valve surgery: a prospective randomized controlled trial.
Investigators: Armin Flinspach, MD, Elisabeth Adam, MD, Department of Anesthesiology, Intensive Care Medicine and Pain Therapy University Hospital Frankfurt, Goethe University Frankfurt.
Following cardiac surgery, sedatives are routinely administered in the intensive care unit (ICU) to facilitate mechanical ventilation. Due to the advancing age of complex cardiac surgery patients, with an increasing prevalence of liver and kidney dysfunction, the metabolism of intravenous sedatives is in part severely impaired and may lead to oversedation, prolonged mechanical ventilation, delirium and drug-induced hypotension. There is increasing data that volatile sedation promotes faster patient awakening and shorter extubation times in the surgical critical care setting. Specifically, (multiple) valve surgery requiring prolonged intervention and time on cardiopulmonary bypass are different from CABG surgery. These variables may lead to different outcomes than in patients following CABG surgery. The aim of the study is to investigate whether patients undergoing cardiac valve surgery will benefit from the postoperative administration of volatile anesthetics.

Title: AnaConDa Device in cardiac surgery : an easy solution to achieve total inhalation anesthesia with sevoflurane.
Investigators: Francois Labaste, MD, Professor Vincent Miniville, Professor Bertrand Marcheix, Service d’anesthesie & ranimation – Chirurgie cardiaque Centre Hospitalier Universitaire de Toulouse.
Volatile (inhaled) anesthetic agents have cardioprotective effects. Administration before a prolonged cardiac ischaemic episode is known as anaesthetic preconditioning. Several clinical studies indicate that volatile anesthetics given during cardiac surgery confer myocardial protection and reduce the risk of perioperative myocardial infarction, myocardial dysfunction, and death. Other randomized trials did not confirm a benefit of volatile anesthetics on long-term mortality but in these, inhaled anaesthetics were not given during cardio-pulmonary bypass (CPB) due to a lack of vaporizing methods during CPB. The research team have found and successfully implemented a method to administer inhaled anaesthetics via the AnaConDa during CPB, enabling total inhaled anesthesia throughout the entire surgical procedure. The main aim of the trial, comparing total inhaled anesthesia and postoperative sedation with intravenous anesthesia and sedation is to describe the feasibility and the safety of use of the AnaConDa during cardiac surgery with CPB.

Sedana Medical Research Foundation 2019 – Awarded projects

In spring 2019, Sedana Medical Research Foundation had its first call for proposals. Many well-written and interesting applications were submitted. After independent scientific review by two external reviewers and prioritization by Sedana Medical´s Clinical Development Committee, three research projects were prioritized for funding in 2019.

Title: Feasibility and safety of inhaled sedation in ECMO patients undergoing ultra-protective low frequency ventilation.
Investigators: Dr Giuseppe Foti, Associate professor and Director and dr Marco Giani, Department of Anesthesia and Intensive Care Department of Monza University Hospital, Italy.
This study will investigate inhaled sedation delivered with the AnaConDa in Acute Respiratory Distress Syndrome (ARDS) patients undergoing veno-venous extracorporeal membrane oxygenation with ultra-protective tidal volumes and low-frequency ventilation. Patients on Extracorporeal membrane oxygenation (ECMO) will receive intravenous sedation and inhaled sedation with sevoflurane in randomized order. Sedation feasibility and sedation offset will be compared between sedation strategies. While retrospective data are promising, a prospective study would confirm that inhaled anaesthetics, that appear to be lung-protective, may be used in patients normally considered too sick for uptake and elimination via the lungs.

Title: : Inhaled anaesthetic effects on Mean Pulmonary Arterial Pressure in ARDS patients.
Investigators: Dr Gabriel Parzy, Dr Jean-Marie Forel, and Dr Laurent Papazian, Professor, Medical Intensive Care Unit service, Intensive Care Unit, Hôpital Nord, Marseille, France.
The main objective in this research project is to investigate potential reduction of mean pulmonary arterial pressure (mPAP) during inhaled sedation via the AnaConDa, in moderate or severe ARDS patients. ARDS is associated with cardiopulmonary complications, including cor pulmonale and carries a high mortality. While inhaled anaesthetics are known to be vasodilatory in general, potential such effects in ARDS are not well studied previously. Mechanically ventilated ARDS patients will receive sevoflurane and mPAP will be measured before and one hour after the introduction of low-dose sevoflurane. Reduction of pulmonary pressures with inhaled anaesthetics may potentially improve outcomes in ARDS patients.

Title: Sevoflurane Sedation in COVID-19 ARDS Patients to Reduce Lung Injury: a Randomized Controlled Trial.
Investigators: Dr Martin Schläpfer, Privatdozent, and Dr Beatrice Beck-Schimmer, Professor, Vice President Medicine, Institutes of Anesthesiology and Physiology, University and University Hospital Zurich, Switzerland.
The purpose of this trial is to study the effect of initial temporary sevoflurane sedation on mortality and persistent organ dysfunction (POD) in survivors at day 28 after ICU admission in the population of patients suffering from COVID-19 ARDS.

The corona virus disease 19 (COVID-19) pandemic, caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is spreading rapidly across Europe. While data from European centers are still missing, several publications from Chinese centers are available.

Respiratory failure from acute respiratory distress syndrome (ARDS) is the leading cause of mortality and may be caused or exacerbated by a ‘cytokine storm syndrome’. Recent trials from our group demonstrated that the volatile anaesthetic sevoflurane administered during ventilation of patients has anti-inflammatory properties. Moreover, in in vivo studies volatile anaesthetics reduce the severity of ARDS compared to intravenous sedation, which has been confirmed in a clinical pilot trial. Attenuating ARDS and thereby improving oxygenation strongly decreases morbidity and mortality of patients.”

Application process

The grant for 2021 will put priority to research targeting effects of inhaled anaesthetics in mechanically ventilated patients in intensive care. High priority will be put to projects investigating the effects of isoflurane. However, well-formulated applications for other sedation-related research may also receive funding.

Applications that do not follow the instructions or are submitted after the deadline will not be assessed.

Up to three individual academic researchers will be awarded a grant of between €10 000 and €30 000 per year, for up to two years.

Application review process

All applications will be assessed by a committee consisting of Chief Medical Officer at Sedana Medical and two independent scientific reviewers. All project information besides the abstract, the applicant information and photo will remain confidential.

Granted applications will be presented on Sedana Medical´s website in September 2021.
Please send your application with the research project headings below to SMRG@sedanamedical.com no later than 31st of July 2021.

We welcome your application.

Click here to download SMRG 2021 – Call for proposals & Instructions